|
|
|
Volumn 84 Suppl EHA-4, Issue , 1999, Pages 94-95
|
|
Chronic lymphocytic leukaemia. Current strategy and new perspectives of treatment.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALEMTUZUMAB;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC ANTIMETABOLITE;
CANCER ANTIBODY;
DRUG DERIVATIVE;
FLUDARABINE;
MONOCLONAL ANTIBODY;
RITUXIMAB;
VIDARABINE;
BONE MARROW TRANSPLANTATION;
CHRONIC LYMPHATIC LEUKEMIA;
CLASSIFICATION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FORECASTING;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMAN;
MORTALITY;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIAL;
REMISSION;
REVIEW;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, NEOPLASM;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC AGENTS;
BONE MARROW TRANSPLANTATION;
CLINICAL TRIALS;
FORECASTING;
HEMATOPOIETIC STEM CELL TRANSPLANTATION;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC;
PROGNOSIS;
RANDOMIZED CONTROLLED TRIALS;
REMISSION INDUCTION;
VIDARABINE;
|
|
EID: 0033139847
PISSN: 03906078
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (21)
|
|
References (10)
|
